Loading...
XIDX
PRDA
Market cap139mUSD
Nov 12, Last price  
2,470.00IDR
Name

Prodia Widyahusada Tbk PT

Chart & Performance

D1W1MN
XIDX:PRDA chart
P/E
8.57
P/S
1.03
EPS
288.21
Div Yield, %
6.72%
Shrs. gr., 5y
Rev. gr., 5y
5.24%
Revenues
2.25t
+1.34%
997,986,700,0791,101,043,712,6121,197,727,222,0121,358,664,085,9761,466,017,000,0001,599,757,000,0001,744,271,000,0001,873,375,000,0002,652,257,000,0002,181,642,000,0002,222,466,000,0002,252,194,000,000
Net income
270.20b
+3.97%
61,590,631,71358,560,231,45559,024,994,42288,134,987,526150,797,000,000175,450,000,000210,261,000,000268,747,000,000623,230,000,000371,647,000,000259,874,000,000270,197,000,000
CFO
476.65b
+15.89%
82,664,729,507105,658,756,890155,608,151,085119,253,694,64093,470,000,000239,829,000,000341,825,000,000434,631,000,000777,266,000,000496,733,000,000411,285,000,000476,645,000,000
Dividend
Apr 29, 2024165.9673 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PT Prodia Widyahusada Tbk provides private clinical laboratory services. The company offers laboratory, panel test, and other diagnostics support services. As of December 31, 2021, it operated 259 outlets comprising 10 Prodia Health Care and specialty clinic outlets, 142 clinical lab and medical labs, 98 point of care outlets, and 9 hospital collaboration labs in 34 provinces throughout Indonesia. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Prodia Widyahusada Tbk is a subsidiary of PT Prodia Utama.
IPO date
Dec 07, 2016
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT